Stocktoria
KALA BIO, Inc. KALA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-07-20
KALA BIO, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.9M | $11.2M |
| SG&A expense | — | — | $20.6M | $65.0M | $105.1M |
| Operating income | -$39.2M | -$41.0M | -$39.7M | -$81.7M | -$130.2M |
| Interest expense | — | — | $5.8M | $7.3M | $8.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$27.0M | -$38.5M | -$42.2M | -$44.8M | -$142.6M |
| EPS (diluted) | $-3.31 | $-10.15 | $-17.35 | $-29.48 | $-108.32 |
| Operating cash flow | -$32.0M | -$29.4M | -$27.9M | -$78.9M | -$108.2M |
| Cash & equivalents | $7.6M | $51.2M | $50.9M | $70.5M | $92.1M |
| Inventory | — | — | — | — | $8.6M |
| Total assets | $9.5M | $55.5M | $55.9M | $86.8M | $139.4M |
| Total liabilities | $2.5M | $43.2M | $48.4M | $67.8M | $122.6M |
| Shareholders' equity | $7.0M | $12.3M | $7.5M | $19.0M | $16.8M |
Source: SEC EDGAR filings · CIK 0001479419 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.